These drugs have acquired a formal liver indication, which is genuinely new and worth understanding precisely. It is narrower than the sentence “approved for liver disease” suggests, and the narrowness is the useful part — the trial behind it has its own page here.
What was approved, and for whom
Two drugs now hold conditional US approval for metabolic dysfunction-associated steatohepatitis with significant fibrosis: resmetirom, a liver-directed thyroid hormone receptor-beta agonist, and semaglutide 2.4 mg. [1] The population is fibrosis stage F2 to F3, without cirrhosis. Earlier stages are not included, and neither is F4.
An international expert panel has now consolidated the phase 3 data, the FDA labels and early clinical experience into one care pathway: how to diagnose MASH with significant fibrosis using non-invasive tests, how to choose and start a therapy, how to monitor, and how to define response, non-response and the criteria for switching or combining the two agents.
Why that matters for what gets sold
Two things follow, and they point in different directions.
The first is that people with significant liver fibrosis are now among the strongest candidates for this drug — and most of them do not know they have it, because MASH is largely silent until it is not. The approval creates a reason to be tested that did not exist when there was nothing to offer.
The second is that the approval attaches to a specific branded product at a specific dose in a specific staged population. Most of what this roster sells is compounded semaglutide, which holds no approved indication for anything. “Semaglutide is approved for liver disease” is a true sentence about Wegovy and a misleading one about a compounded vial, and the distance between those two is the kind of thing almost nobody here spells out.
Monitoring is part of the indication
The panel devotes substantial attention to on-treatment monitoring and response assessment, including what counts as non-response and when to switch or combine. That is a treatment relationship with a clinician who is tracking something over time.
It is also the part of the framework a website transaction is least equipped to supply — the same gap a European specialist society described as Right Data and Right Care, and the same reason nutritional monitoring goes undone for people buying remotely. A drug with a monitoring protocol sold without one is not the same treatment the approval describes.
What to take from it
If you have risk factors for fatty liver disease — type 2 diabetes, obesity, high triglycerides — there is now a reason to ask about fibrosis staging that did not exist three years ago, and the tests are non-invasive. That is a conversation with a clinician, not a purchase.
And if you are already taking one of these drugs for weight, the panel explicitly addresses managing patients who arrive already on a GLP-1. That is worth knowing: the question of what to do about somebody who started for one reason and turns out to qualify for another is one the specialists have now written down, and the answer is not the same as continuing unchanged.